Faithward Advisors’s Jazz Pharmaceuticals JAZZ Stock Holding History

Faithward Advisors’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.31M	Sell	30,331 -8,008	-21%	-$1.75M	0.89%	28
2026 Q1	$7.72M	Buy	38,339 +9,065	+31%	+$1.58M	1.1%	23
2025 Q4	$4.98M	Buy	29,274 +1,370	+5%	+$210K	0.73%	37
2025 Q3	$3.68M	Buy	27,904 +13,475	+93%	+$1.62M	0.55%	60
2025 Q2	$1.53M	Buy	14,429 +663	+5%	+$72K	0.24%	86
2025 Q1	$1.71M	Sell	13,766 -557	-4%	-$72.7K	0.3%	80
2024 Q4	$1.76M	Buy	14,323 +460	+3%	+$54.2K	0.3%	80
2024 Q3	$1.54M	Sell	13,863 -257	-2%	-$28.2K	0.27%	90
2024 Q2	$1.51M	Buy	14,120 +261	+2%	+$28.7K	0.27%	89
2024 Q1	$1.67M	Buy	13,859 +165	+1%	+$20.2K	0.3%	77
2023 Q4	$1.67M	Buy	13,694 +2,780	+25%	+$347K	0.37%	65
2023 Q3	$1.33M	Buy	+10,914	New	+$1.45M	0.32%	67

Other funds holding JAZZ

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

Faithward Advisors's JAZZ Position: Q2 2026 in Review

Faithward Advisors reduced its Jazz Pharmaceuticals (JAZZ) stake by 21% in Q2 2026, selling an estimated $1.75M and leaving 30,331 shares worth $7.31M. The position accounts for 0.89% of the portfolio, ranked #28.

Faithward Advisors first reported a position in JAZZ in Q3 2023 and has held it in 12 quarters since. The position peaked at $7.72M in Q1 2026. 646 funds tracked by Wall St. Rank hold JAZZ as of Q2 2026.

Faithward Advisors held 30,331 shares of Jazz Pharmaceuticals worth $7.31M as of Q2 2026.
Faithward Advisors sold 8,008 Jazz Pharmaceuticals shares in Q2 2026, an estimated $1.75M.
Jazz Pharmaceuticals made up 0.89% of Faithward Advisors's portfolio in Q2 2026, its #28 holding.
Faithward Advisors first reported a position in Jazz Pharmaceuticals in Q3 2023 and has held it in 12 quarters since.
Faithward Advisors's Jazz Pharmaceuticals position peaked at $7.72M in Q1 2026.
646 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2026.

Based on Faithward Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.